Efficacy and safety of eribulin in the treatment of advanced adult soft tissue sarcoma (STS): First real-world data in Chinese population.

被引：0
|
作者：
Guo, Xi [1 ]
Zhou, Yuhong [1 ]
Zhuang, Rongyuan [1 ]
You, Yang [1 ]
Zhang, Chenlu [1 ]
Wang, Zhiming [1 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11577
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world data of a cohort of patients with soft tissue sarcoma in a single institution of Colombia.
    Eduardo Pino, Luis
    Camilo Triana, Ivan
    Ospina Serrano, Aylen Vanessa
    Segovia, Javier
    Carolina Hennessey, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data
    Le Cesne, Axel
    FUTURE ONCOLOGY, 2022, 18 (30S) : 1 - 3
  • [33] EFFICACY AND SAFETY OF ABATACEPT IN CHINESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: REAL-WORLD DATA
    Qing, Y. F.
    Huang, Q.
    Zhao, Z. Y.
    Zhang, Q. B.
    Li, L. Q.
    Wen, Z.
    You, Z. X.
    Tang, H.
    Xu, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1291 - 1292
  • [34] Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): A single-center, real-world study
    Yang, Jin
    Yang, Jiao
    Wang, Guangxi
    Zhang, Haochen
    Zhao, Shidi
    Zhao, Xiaoai
    Dong, Danfeng
    Wang, Le
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] A nomogram to predict the prognosis of advanced soft tissue sarcoma patients treated with anlotinib: A real-world population-based study.
    Bin Wang
    Liu, Jie
    Zhang, Ren Shu
    Jiang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
    Colbert, Gates
    Sannapaneni, Shilpa
    Lerma, Edgar, V
    DRUG HEALTHCARE AND PATIENT SAFETY, 2022, 14 : 87 - 96
  • [37] Efficacy and safety of anlotinib combined with liposomal doxorubicin in first-line treatment of advanced soft-tissue sarcoma.
    Sun, Xin
    Guo, Wei
    Zhang, Ranxin
    Xie, Lu
    Xu, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
    Peng, Lixiu
    Guo, Jun
    Kong, Li
    Huang, Yong
    Tang, Ning
    Zhang, Juguang
    Wang, Minglei
    He, Xiaohan
    Li, Zhenzhen
    Peng, Yonggang
    Wang, Zhehai
    Han, Xiao
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [39] Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study
    Liu, Jie
    Deng, Yaotiao
    Wang, Ying
    Zhang, Jie
    Li, Mei
    Jiang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] OUTCOME OF FIRST-LINE TREATMENT OF ELDERLY ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS: A POOLED ANALYSIS OF ELEVEN EORTC SOFT TISSUE AND BONE SARCOMA GROUP TRIALS
    van der Graaf, W. T. A.
    Le Cesne, A.
    Mir, O.
    Gelderblom, H.
    Italiano, A.
    Marreaud, S.
    Judson, I.
    Litiere, S.
    ANNALS OF ONCOLOGY, 2014, 25
12345